Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Alessandro M. Minisini"'
Autor:
Francesca Galardi, Francesca De Luca, Chiara Biagioni, Ilenia Migliaccio, Giuseppe Curigliano, Alessandro M. Minisini, Martina Bonechi, Erica Moretti, Emanuela Risi, Amelia McCartney, Matteo Benelli, Dario Romagnoli, Silvia Cappadona, Stefano Gabellini, Cristina Guarducci, Valerio Conti, Laura Biganzoli, Angelo Di Leo, Luca Malorni
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-12 (2021)
Abstract Background Circulating tumor cells (CTCs) are prognostic in patients with advanced breast cancer (ABC). However, no data exist about their use in patients treated with palbociclib. We analyzed the prognostic role of CTC counts in patients en
Externí odkaz:
https://doaj.org/article/2bff5be9c34644208616c14bb489fbff
Autor:
Lorenzo Rossi, Chiara Biagioni, Amelia McCartney, Ilenia Migliaccio, Giuseppe Curigliano, Giuseppina Sanna, Erica Moretti, Alessandro M. Minisini, Saverio Cinieri, Carlo Tondini, Grazia Arpino, Antonio Bernardo, Angelo Martignetti, Emanuela Risi, Marta Pestrin, Luca Boni, Matteo Benelli, Laura Biganzoli, Angelo Di Leo, Luca Malorni
Publikováno v:
Breast Cancer Research, Vol 21, Iss 1, Pp 1-7 (2019)
Abstract Currently, there is limited data regarding the effectiveness of standard subsequent line therapies such as endocrine therapy, chemotherapy, or targeted agents after progression on CDK4/6 inhibitor-based regimens. This paper describes time-to
Externí odkaz:
https://doaj.org/article/7597ce6a4a454fd6a655f6904551e47c
Autor:
Harriet Johansson, Giuseppe Spadola, Giulio Tosti, Mario Mandalà, Alessandro M. Minisini, Paola Queirolo, Valentina Aristarco, Federica Baldini, Emilia Cocorocchio, Elena Albertazzi, Leonardo Zichichi, Saverio Cinieri, Costantino Jemos, Giovanni Mazzarol, Patrizia Gnagnarella, Debora Macis, Ines Tedeschi, Emanuela Omodeo Salè, Luigia Stefania Stucci, Bernardo Bonanni, Alessandro Testori, Elisabetta Pennacchioli, Pier Francesco Ferrucci, Sara Gandini, on behalf of the Italian Melanoma Intergroup (IMI)
Publikováno v:
Nutrients, Vol 13, Iss 6, p 1931 (2021)
Patients with newly resected stage II melanoma (n = 104) were randomized to receive adjuvant vitamin D3 (100,000 IU every 50 days) or placebo for 3 years to investigate vitamin D3 protective effects on developing a recurrent disease. Median age at di
Externí odkaz:
https://doaj.org/article/a069b3564e7d490cb895ffd52b88cc1e
Autor:
Meredith M Regan, Barbara A Walley, Gini F Fleming, Prudence A Francis, Marco A Colleoni, István Láng, Henry L Gómez, Carlo A Tondini, Harold J Burstein, Matthew P Goetz, Eva M Ciruelos, Vered Stearns, Hervé R Bonnefoi, Silvana Martino, Charles E Geyer, Claudio Chini, Alessandro M Minisini, Simon Spazzapan, Thomas Ruhstaller, Eric P Winer, Barbara Ruepp, Sherene Loi, Alan S Coates, Aron Goldhirsch, Richard D Gelber, Olivia Pagani
Publikováno v:
Cancer Research. 82:GS2-05
Background The updated combined SOFT+TEXT analysis, after 9 years median follow-up (MFU), revealed that adjuvant E+OFS vs T+OFS significantly improved disease-free survival (DFS) and distant recurrence-free interval (DRFI) but not overall survival (O